AVITA Medical Reports Complete Cohealyx I Data in Full-Thickness Wounds Showing Earlier Graft Readiness and Six-Month Healing Outcomes
AVITA Medical announced complete results from its Cohealyx I study, demonstrating significantly earlier readiness for skin grafting and improved six-month healing outcomes in full-thickness wounds. The study showed a median graft readiness of 11 days, with 72% of wounds ready within two weeks, and reported no Cohealyx-related adverse events, along with improving scar scores. These findings support the use of Cohealyx for preparing complex wounds for skin grafting, enhancing confidence among clinicians.
AVITA Medical reports six-month Cohealyx wound study results
AVITA Medical announced the complete results of its Cohealyx I study, including six-month follow-up data for patients with full-thickness wounds. The study successfully met its primary endpoint, showing a mean time to graft readiness of 13.6 days, significantly faster than the 28-day performance goal. Additionally, 88% of patients achieved wound healing by eight weeks after grafting, with improved scar appearance over 26 weeks and no reported Cohealyx-related adverse events.
Avita Medical Issues 267,533 Common Stock Shares Following Warrant Exercises by Perceptive and OrbiMed on 12 November 2026
Avita Medical Inc. (ASX:AVH) issued 267,533 shares of common stock on November 12, 2026, after cashless warrant exercises by Perceptive Credit Holdings V, LP and OrbiMed Royalty & Credit Opportunities IV, LP. Perceptive received 119,375 shares and OrbiMed received 148,158 shares, with the remaining shares withheld for the exercise prices. These newly issued shares rank equally with existing securities of the same class.
Avita Medical (NASDAQ:RCEL) Stock Rating Raised to Buy at Wall Street Zen
Avita Medical (NASDAQ:RCEL) recently received an upgrade from "hold" to "buy" by Wall Street Zen. This aligns with other analysts, resulting in a "Moderate Buy" consensus rating and a target price of $16.60. The company also reported strong quarterly earnings, beating analyst estimates for both EPS and revenue.
Avita Medical reports warrant exercises by Perceptive and OrbiMed investors By Investing.com
Avita Medical (NASDAQ:RCEL) announced that Perceptive Credit Holdings V, LP and OrbiMed Royalty & Credit Opportunities IV, LP have exercised previously issued warrants for common stock. Perceptive exercised a warrant for 119,375 shares, while OrbiMed exercised a warrant for 148,158 shares, both through cashless processes. These exercises occur as Avita Medical's stock has seen a significant 370% year-to-date surge, with the company also reporting strong Q3 2026 results and raising its full-year sales outlook.
Form 8K Avita Medical Ltd For: 13 November By Investing.com
Avita Medical Ltd (RCEL) filed a Form 8K on November 13, 2026. This SEC filing is a common requirement for companies to announce significant events that investors should know about. The article highlights the filing date and includes the company's stock symbol and current performance.
Form 8K Avita Medical Ltd For: 13 November By Investing.com
Avita Medical Ltd (RCEL) filed a Form 8K on November 13, 2026. This filing, announced by Investing.com, indicates a significant event that the company is required to disclose to the SEC, though the specific details of the event are not provided in this brief announcement. The company's stock, RCEL, was trading down by 3.52% at the time of the article's publication.
TD Cowen maintains AVITA Medical at Buy, raises price target to $22 from $20
TD Cowen has reiterated its "Buy" rating for AVITA Medical (RCEL) and increased its price target from $20 to $22. This new price target suggests an upside of 27.2% from the stock's closing price of $17.30 on November 11.
Avita Medical (NASDAQ:RCEL) Given New $22.00 Price Target at TD Cowen
TD Cowen has increased its price target for Avita Medical (NASDAQ:RCEL) to $22.00, up from $20.00, while maintaining a "buy" rating, indicating a potential upside of 25.93%. This positive outlook aligns with the company's recent strong quarterly earnings, where it surpassed analyst expectations for both EPS and revenue. Other brokerages have also adjusted their ratings and price targets for RCEL, contributing to a "Moderate Buy" consensus rating with an average target price of $16.60.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in regenerative medicine, announced it will host an investor webinar briefing to discuss its third-quarter 2026 financial results. The webinar, featuring CEO Jim Corbett and CFO David Medeiros, will also provide a business update and outlook.
AVITA Medical raises guidance as Medicare locks in RECELL payment codes
AVITA Medical has increased its full-year revenue guidance and removed the going concern qualification from its accounts, driven by a 53% year-over-year revenue growth in the third quarter to US$26.1 million. The company's RECELL system remains a primary growth driver, with US revenue reaching US$22.4 million. This positive outlook is further bolstered by the US Centres for Medicare and Medicaid Services finalizing national physician payment values and simpler billing codes for RECELL procedures, effective January 1, 2027.
Investors can submit questions for AVITA Medical’s leaders on Nov. 11
AVITA Medical (RCEL) will host an investor webinar on November 11, 2026, to discuss its third-quarter financial and business results. The briefing will feature CEO Cary Vance and CFO David O’Toole, followed by a Q&A session where participants can submit questions. A replay of the webinar will be available on the company's investor relations website.
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) is set to host an investor webinar briefing and presentation on November 11, 2026, featuring CEO Cary Vance and CFO David O'Toole. The briefing will cover financial and business results from the recent third-quarter 2026 earnings webcast, concluding with a Q&A session for shareholders and prospective investors. A replay of the event will be available on the company's website following the presentation.
Lake Street maintains AVITA Medical at Buy, raises price target to $20 from $12
Lake Street has reiterated its "Buy" rating for AVITA Medical (RCEL) and increased its price target from $12 to $20, marking a 66.7% raise. This new price target suggests an upside of 20.6% compared to the closing price of $16.59 on November 6. Investors can find more detailed analyst data and ratings for AVITA Medical on the Forecasts tab and track recommendations in the News Flow section.
Avita Medical Q3 Earnings Call Highlights
Avita Medical raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales increased 53%, driven by strong demand for its RECELL wound treatment system and growing adoption of Cohealyx. The company reported $26.1 million in revenue and reduced quarterly cash use, reaffirming its expectation to reach cash flow breakeven in the fourth quarter. New physician billing codes for skin cell suspension autografting are scheduled to take effect in January 2027, which is expected to further support RECELL adoption.
AVITA Medical (RCEL) Q3 2026 Earnings Call Transcript
AVITA Medical reported a 53% year-over-year revenue increase to $26.1 million in Q3 2026, driven by strong adoption of its RECELL system and growth in Cohealyx. The company significantly reduced its cash use and raised its full-year revenue guidance to $92-$94 million, expecting to achieve cash flow breakeven in Q4. Management emphasized expanding its commercial footprint in burn and trauma centers and leveraging its integrated wound care portfolio.
AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53% as AVITA ...
AVITA Medical Inc (AVHHL) reported a strong Q3 2026, with revenue surging 53% year over year to $26.1 million, driven by robust U.S. Resell revenue and improved gross margins. The company raised its full-year revenue guidance for the second consecutive quarter to $92-$94 million and expects to reach cash flow breakeven in Q4. Key growth drivers for 2027 include a new CPT reimbursement framework and expanded adoption of its product portfolio, while maintaining disciplined operating expenses.
AVITA Medical's 53% Growth And Second Guidance Raise Remove Going-Concern Doubt, But A Flat Q4 Guide Tests A Stock Up 171%
AVITA Medical (RCEL) reported strong Q3 results with revenue up 53.1% year-over-year and a narrowed net loss, leading to a second full-year guidance raise and the removal of going-concern doubt. While growth accelerated and operating leverage improved, the Q4 guidance implies a sequential pause, and the company still relies on borrowed capital. The stock has risen 171.5% since August, suggesting much of the turnaround is already priced in, and investors will seek further evidence of sustained sequential growth from future catalysts.
Avita Medical Files Form 10-Q for Quarter Ended September 30, 2026 with 31,420,219 Shares Outstanding
Avita Medical, Inc. (ASX:AVH) has filed its quarterly report on Form 10-Q with the SEC for the period ended September 30, 2026, reporting 31,420,219 shares of common stock outstanding as of November 2, 2026. The company is incorporated in Delaware, headquartered in Valencia, California, and listed on both Nasdaq (RCEL) and ASX (AVH). The filing includes consolidated financial statements and notes that there have been no material changes to the Risk Factors previously described in its 2025 Annual Report on Form 10-K.
AVITA Medical raises 2026 guidance after strong revenue growth
AVITA Medical reported a 53% year-over-year increase in third-quarter revenue, reaching US$26.1 million and surpassing analyst estimates. This strong performance, driven by its RECELL and Cohealyx product lines, led the company to raise its full-year 2026 revenue guidance to between US$92 million and US$94 million. Additionally, AVITA Medical confirmed its expectation to achieve cash flow breakeven in the fourth quarter of 2026 and secured access to a US$10 million credit facility.
AVITA Medical, Inc. (RCEL) Tops Q3 EPS by 4c ; Offers Guidance
AVITA Medical, Inc. (RCEL) reported better-than-expected Q3 EPS of ($0.20), beating the analyst estimate by $0.04, and revenue of $26.11 million, surpassing the consensus estimate. However, the company offered FY2026 revenue guidance of $92-94 million, which is significantly below the consensus estimate of $121.2 million.
AVITA Medical Reports Third Quarter Results
AVITA Medical announced strong third-quarter 2026 financial results, achieving 53% year-over-year revenue growth to $26.1 million, driven by the success of RECELL and Cohealyx. The company raised its full-year 2026 revenue guidance to $92 million to $94 million and reaffirmed its expectation of reaching cash flow breakeven in Q4 2026. This performance allowed the company to access an additional $10 million under its credit facility and remove the "going concern" qualification.
AVITA Medical Reports Third Quarter Results
AVITA Medical reported strong third-quarter 2026 results with revenue rising 53% year-over-year to $26.1 million and gross margin increasing to 84.0%. The company narrowed its net loss to $6.2 million and raised its full-year 2026 revenue guidance to $92 million–$94 million, reaffirming its expectation for cash flow breakeven in Q4 2026. These positive financial and operational updates, including the removal of the "going concern" qualification, reflect continued commercial momentum and improved liquidity.
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
AVITA Medical announced that the Centers for Medicare & Medicaid Services (CMS) have finalized national physician valuations and a simplified four-code Current Procedural Terminology (CPT) billing structure for RECELL procedures, effective January 1, 2027. These changes are expected to streamline reporting and provide greater payment predictability for physicians using RECELL for burn and wound injuries. The new framework will replace regionally determined valuations with nationally published Relative Value Units (RVUs).
Avita Medical Issues 387,716 Common Stock Shares After Perceptive Warrant Cashless Exercise on 29 October 2026
Avita Medical Inc. (ASX:AVH) has issued 387,716 shares of common stock following a cashless exercise of a warrant by Perceptive Credit Holdings V, LP on October 29, 2026. Perceptive exercised its warrant for 500,000 shares, with Avita Medical withholding 112,284 shares for the exercise price. This transaction brings Avita Medical's total quoted CHESS Depositary Interests on ASX to 69,302,630 securities.
AVITA Medical Issues 387,716 Shares After Perceptive Warrant Exercise
AVITA Medical (RCEL) issued 387,716 shares to Perceptive after a cashless exercise of a warrant for up to 500,000 shares. Perceptive exercised the warrant on October 26, 2026, under a credit agreement with AVITA Medical, with the shares issued on October 28. The company lodged disclosures about this exercise with the Australian Securities Exchange.
How Has AVITA Medical (ASX:AVH) Recorded a 307% One-Year Share Gain?
AVITA Medical (ASX:AVH) experienced a 307% share price gain over one year, reaching AUD 4.69 on October 30, 2026. This surge followed the release of positive clinical and economic findings for its PermeaDerm product, which showed a 70% lower treatment-product cost and comparable wound healing outcomes to allograft in a 40-patient study. The article discusses these study results, the product's role in AVITA's portfolio, and broader healthcare market considerations.
AVITA Medical, Inc. (AVH.XA) Seasonal returns chart
This article presents a seasonal returns chart for AVITA Medical, Inc. (AVH.XA), showcasing the average monthly price return between 2016 and 2026. It highlights the stock's performance with a current quote of 4.4221, down 5.71%, and provides navigation to various financial data sections like news, statistics, and historical data.
AVITA Medical, Inc. (AVH.XA) Seasonal Returns Chart - Yahoo Finance
The article displays the seasonal returns chart for AVITA Medical, Inc. (AVH.XA) on Yahoo Finance, showing the average monthly price return from 2016 to 2026. At the time of the data capture, AVITA Medical's stock was trading at 4.4221 AUD, down 5.71%.
Avita Medical (RCEL) Projected to Release Earnings on Thursday
Avita Medical (NASDAQ:RCEL) is anticipated to release its Q3 2026 earnings after market close on Thursday, November 5th. Analysts are forecasting a loss of $0.2394 per share on revenues of $22.35 million. The company has a "Moderate Buy" consensus rating from analysts, with a target price of $12.20, while shares recently opened at $16.50, close to their 52-week high.
AVITA Medical, Inc. (RCEL) Seasonal returns chart
The article presents a seasonal returns chart for AVITA Medical, Inc. (RCEL), showing the average monthly price return from 2016 to 2026. It highlights the stock's performance with its current price and daily change, alongside typical Yahoo Finance market data and company information. The chart is a visual representation of historical seasonality for the stock.
Avita Medical, Inc. Estimates – NASDAQ:RCEL
This page on TradingView provides financial actuals and analyst estimates for Avita Medical, Inc. (NASDAQ: RCEL). It allows users to explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
AVITA Medical (ASX:AVH) Is Up 246.03%: Is It Still Worth a Closer Look?
AVITA Medical (ASX:AVH) shares have increased by 246.03% recently, with a 9.27% gain on October 22, 2026, closing at $4.36. The company reported record Q2 2026 net revenue of $21.7 million, an 18% year-on-year increase, and raised its full-year 2026 revenue guidance to $86–89 million, expecting to achieve cash flow breakeven in Q4 2026. This performance and future outlook suggest continued momentum, although regulatory decisions and commercial uptake remain key factors for future growth.
AVITA Medical (ASX:AVH) Is Up 246.03%: Is It Still Worth a Closer Look?
AVITA Medical (ASX:AVH) shares have seen a significant gain of 246.03%, with a 9.27% increase on October 22, 2026. The company reported record Q2 net revenue of $21.7 million, an 18% year-on-year increase, and raised its full-year 2026 revenue guidance to $86–89 million, expecting to achieve cash flow breakeven in Q4 2026. This positive performance is driven by strong adoption of its RECELL system and other products, alongside favorable proposed Medicare payment updates.
AVITA Medical to Release Third Quarter 2026 Financial Results on 5 November
AVITA Medical, Inc. (ASX:AVH) announced it will release its third-quarter 2026 financial results after the U.S. financial markets close on Thursday, November 5, 2026. A conference call and webcast will be held the same day at 1:30 p.m. Pacific Time to discuss the results and recent business developments. The company's flagship product, RECELL, is approved for thermal burn and trauma wounds, and AVITA Medical also holds rights for other wound care products globally.
AVITA Medical to Announce Third Quarter 2026 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced it will report its third quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will host a conference call and webcast on the same day to discuss results and business highlights. Further details for webcast registration and conference call participation were provided.
A live call on AVITA Medical’s third-quarter results is set for Nov. 5 at 1:30 p.m. Pacific.
AVITA Medical (RCEL) will report its third-quarter 2026 financial results after U.S. financial markets close on November 5, 2026. A conference call and webcast will be held that same day at 1:30 p.m. Pacific Time to discuss the results and recent business highlights. A replay of the event will be available on the company's investor relations website.
AVITA Medical to Announce Third Quarter 2026 Financial Results
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced it will report its third quarter 2026 financial results on Thursday, November 5, 2026, after U.S. financial markets close. The company will host a conference call and webcast to discuss these results and recent business highlights at 1:30 p.m. Pacific Time on the same day. AVITA Medical specializes in acute wound care solutions, including its FDA-approved RECELL technology.
What Comes Next For AVITA Medical After A 276% Gain
AVITA Medical has seen a significant 276% gain for investors this year, driven by progress in Medicare reimbursement and wider adoption of its RECELL product. The company's Q2 2026 results showed increased revenue and an improved loss margin, supporting an optimistic outlook. However, its current trading price of US$13.04 is above the Narrative's estimated Fair Value, suggesting that future growth relies on continued broad hospital uptake and efficient execution.
BTIG raises target for Avita Medical stock from USD 11.00 to USD 15.00
BTIG has increased its price target for Avita Medical (RCEL) from USD 11.00 to USD 15.00, maintaining a Buy rating, following strong second-quarter results and raised revenue guidance. Avita Medical reported USD 21.70 million in second-quarter revenue, an 18% year-over-year increase, and updated its full-year 2026 revenue guidance to USD 86 million to USD 89 million. The company is also projected to achieve cash flow breakeven in the fourth quarter of 2026.
Is AVITA Medical (ASX:AVH) Close to Cash Flow Breakeven?
AVITA Medical (ASX:AVH) recently hit a yearly high after raising its full-year revenue guidance and reporting record second-quarter revenue. The company, which develops the RECELL system for burns and wounds, anticipates reaching cash flow breakeven in the final quarter of the current year. Investors are now awaiting the third-quarter results for updates on its progress toward this significant milestone.
AVITA Medical Inc (51KB.HM) stock price, news, quote and history
This Yahoo Finance page provides detailed information about AVITA Medical Inc (51KB.HM) stock, including its current price, news, and historical data. As of October 16, 2026, the stock was trading at 2.3300 EUR, up 4.02%. The page also includes performance overview data, comparing the stock's returns against the S&P 500.
AVITA Medical Inc (51KB.HM) analyst ratings, estimates and forecasts
This page provides analyst ratings, estimates, and forecasts for AVITA Medical Inc (51KB.HM) as listed on Yahoo Finance. It displays current stock performance, showing a gain of 4.02% at the close on October 16. The page also includes sections for growth estimates, though specific data for AVITA Medical Inc is not provided.
AVITA Medical CEO Vance to Present at Canaccord Genuity Conference
AVITA Medical Inc. CEO Cary Vance will present at the Canaccord Genuity 46th Annual Growth Conference in Boston from August 11–13, 2026. He is scheduled to speak on August 12 at 8:00 a.m. ET, discussing the company's strategic direction and its FDA-approved RECELL technology for wound care. A live webcast and replay will be available for remote investors.
AVITA Medical schedules investor webinar for August 12
AVITA Medical (NASDAQ: RCEL, ASX: AVH) has scheduled an investor webinar for August 12, 2026, to discuss its Q2 2026 financial results. CEO Cary Vance and CFO David O’Toole will lead the session, focusing on operational outcomes and answering investor questions. The company will also highlight its RECELL technology and exclusive distribution rights for Cohealyx and PermeaDerm in the acute wound care sector.
AVITA Medical Inc (51KB.HM) latest press releases and corporate news
The article provides an overview of AVITA Medical Inc (51KB.HM) on Yahoo Finance, showing its stock performance and basic company information. It indicates that there are currently no news stories or press releases available for the company. The page also presents market data for various indices and currencies.
BTIG Maintains Avita Medical(RCEL.US) With Buy Rating, Raises Target Price to $15
BTIG has reiterated its Buy rating for Avita Medical (RCEL.US) and increased its target price to $15. This suggests a positive outlook from the firm regarding the company's future performance and stock value.
RCEL Maintained by BTIG -- Price Target Raised to $15.00
BTIG has reiterated a "Buy" rating for AVITA Medical (RCEL) and increased its price target from $11.00 to $15.00, reflecting optimism about the company's growth in the regenerative medicine sector. Despite this positive analyst sentiment, the stock is considered approximately 25.8% overvalued according to GuruFocus's GF Value™, with concerns noted about its financial strength and profitability. Investors are advised to consider these valuation and financial health factors alongside the growth prospects before making investment decisions.
AVITA Medical Q2 2026 Earnings Call Transcript
AVITA Medical reported strong Q2 2026 revenue of $21.7 million, an 18% year-over-year increase, driven by the expanding use of its acute wound care portfolio, especially RECELL. The company raised its full-year 2026 revenue guidance to $86-89 million and expects to achieve cash flow breakeven by Q4 2026. Gross margin improved to 81.9%, and operating expenses remained stable, reflecting disciplined commercial execution and efficiency.
AVITA Medical Q2FY26 Results: Revenue up 18% YoY to $21.7 million, guidance raised
AVITA Medical reported an 18% year-over-year revenue increase to $21.7 million in Q2 FY26, marking the first time quarterly revenue exceeded $20 million. The company raised its full-year 2026 revenue guidance to $86-89 million and achieved a narrower net loss of $7.7 million. Management aims for cash flow breakeven and positive cash generation by Q4 2026, supported by sustained growth, maintained gross margins, and controlled operating expenses.